(Q44792435)

6 December 2017

title

Open label study of the effect of amantadine on weight gain induced by olanzapine (English)

1 reference

6 December 2017

1 reference

Won-Myong Bahk

1

1 reference

6 December 2017

Kyoung-Uk Lee

2

1 reference

6 December 2017

Jeong-Ho Chae

3

1 reference

6 December 2017

Chi-Un Pae

4

1 reference

6 December 2017

Taeyoun Jun

5

1 reference

6 December 2017

Kwang-Soo Kim

6

1 reference

6 December 2017

language of work or name

1 reference

1 April 2004

1 reference

Psychiatry and Clinical Neurosciences

6 December 2017

published in

1 reference

6 December 2017

volume

58

1 reference

6 December 2017

issue

2

1 reference

6 December 2017

page(s)

163-167

1 reference

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2003.01211.X

Current estimates of the economic cost of obesity in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2003.01211.X

Effect of amantadine on weight gain during olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2003.01211.X

Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2003.01211.X

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2003.01211.X

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2003.01211.X

Weight gain associated with neuroleptic medication: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2003.01211.X

Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2003.01211.X

Psychosis in Parkinson's disease: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2003.01211.X

The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2003.01211.X

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2003.01211.X

Amantadine in the Treatment of Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2003.01211.X

Sodium valproate in schizophrenia: some biochemical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2003.01211.X

Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2003.01211.X

10.1111/J.1440-1819.2003.01211.X

21 January 2018

Identifiers

DOI

1 reference

6 December 2017

1 reference